These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 7226751)

  • 1. Effect of propranolol treatment on serum prolactin level in schizophrenic patients.
    Elizur A; Segal Z; Yeret A; Ben-David M
    Commun Psychopharmacol; 1980; 4(3):203-6. PubMed ID: 7226751
    [No Abstract]   [Full Text] [Related]  

  • 2. Serum prolactin as a correlate of clinical response to haloperidol.
    Van Putten T; Marder SR; Mintz J
    J Clin Psychopharmacol; 1991 Dec; 11(6):357-61. PubMed ID: 1770154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prolactinemia and predictability of therapeutic response of schizophrenic patients in acute decompensation].
    Vanelle JM; Amorim P; Piketti ML; Bourdel MC; Poirier-Littré MF
    Encephale; 1996 Oct; 22 Spec No 3():82-4. PubMed ID: 8954284
    [No Abstract]   [Full Text] [Related]  

  • 4. Coadministration of fluvoxamine increases serum concentrations of haloperidol.
    Daniel DG; Randolph C; Jaskiw G; Handel S; Williams T; Abi-Dargham A; Shoaf S; Egan M; Elkashef A; Liboff S
    J Clin Psychopharmacol; 1994 Oct; 14(5):340-3. PubMed ID: 7806690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The effect of propranolol, neuroleptics and their combination on serum prolactin levels of schizophrenic patients].
    Elizur A; Segal Z; Yeret A; Aboo-Shach M; Ben-David M
    Harefuah; 1979 Sep; 97(5-6):101-4. PubMed ID: 44254
    [No Abstract]   [Full Text] [Related]  

  • 6. A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation.
    Chouinard G; Safadi G; Beauclair L
    J Clin Psychopharmacol; 1994 Dec; 14(6):377-84. PubMed ID: 7884017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective clinical response at low plasma levels of haloperidol in Japanese schizophrenics with acute psychotic state.
    Jibiki I; Kubota T; Fujimoto K; Sakamoto H; Hasegawa M; Furuta H; Yamaguchi N
    Jpn J Psychiatry Neurol; 1993 Sep; 47(3):627-9. PubMed ID: 8301878
    [No Abstract]   [Full Text] [Related]  

  • 8. Negative correlation between alpha-1-acid-glycoprotein plasma level and response to haloperidol in the acute treatment of schizophrenia.
    Levinson I; Levine S
    Biol Psychiatry; 1995 Aug; 38(3):198-200. PubMed ID: 7578667
    [No Abstract]   [Full Text] [Related]  

  • 9. Haloperidol: therapeutic window in schizophrenia.
    Palao DJ; Arauxo A; Brunet M; Bernardo M; Haro JM; Ferrer J; Gonzalez-Monclus E
    J Clin Psychopharmacol; 1994 Oct; 14(5):303-10. PubMed ID: 7806684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relation of serum molindone levels to serum prolactin levels and antipsychotic response.
    Pandurangi AK; Narasimhachari N; Blackard WG; Landa BS
    J Clin Psychiatry; 1989 Oct; 50(10):379-81. PubMed ID: 2676994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial.
    Leiderman E; Zylberman I; Zukin SR; Cooper TB; Javitt DC
    Biol Psychiatry; 1996 Feb; 39(3):213-5. PubMed ID: 8837983
    [No Abstract]   [Full Text] [Related]  

  • 12. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics.
    Szymanski S; Lieberman J; Pollack S; Kane JM; Safferman A; Munne R; Umbricht D; Woerner M; Masiar S; Kronig M
    Biol Psychiatry; 1996 Feb; 39(4):249-54. PubMed ID: 8645771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acutely psychotic patients receiving high-dose haloperidol therapy.
    Remington G; Pollock B; Voineskos G; Reed K; Coulter K
    J Clin Psychopharmacol; 1993 Feb; 13(1):41-5. PubMed ID: 8486816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Propranolol in schizophrenia. Clinical, metabolic, and pharmacological findings.
    Hanssen T; Heyden T; Sundberg I; Alfredsson G; Nybäck H; Wetterberg L
    Arch Gen Psychiatry; 1980 Jun; 37(6):685-90. PubMed ID: 7387339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond the therapeutic window: a case presentation.
    Schulz SC; Butterfield L; Garicano M; Narasimhachari N; Friedel RO
    J Clin Psychiatry; 1984 May; 45(5):223-5. PubMed ID: 6725212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The assessment and clinical implications of haloperidol acute-dose, steady-state, and withdrawal pharmacokinetics.
    Khot V; DeVane CL; Korpi ER; Venable D; Bigelow LB; Wyatt RJ; Kirch DG
    J Clin Psychopharmacol; 1993 Apr; 13(2):120-7. PubMed ID: 8463444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatosensory-evoked potential changes during haloperidol treatment of chronic schizophrenics.
    Saletu B; Saletu M; Itil T; Marasa J
    Biol Psychiatry; 1971; 3(4):299-307. PubMed ID: 5163816
    [No Abstract]   [Full Text] [Related]  

  • 18. High-dosage neuroleptic therapy for acute schizophrenic patients--two double-blind studies with benperidol.
    Nedopil N; Eben E; Klein H; Krüger R; Rüther E; Schmauss M
    Pharmacopsychiatry; 1985 Jan; 18(1):63-6. PubMed ID: 3887439
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacokinetic protocol for predicting plasma haloperidol concentrations.
    Miller DD; Perry PJ; Kelly MW; Coryell WH; Arndt SV
    J Clin Psychopharmacol; 1990 Jun; 10(3):207-12. PubMed ID: 2376619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostaglandin E1 treatment of schizophrenia.
    Kaiya H
    Biol Psychiatry; 1984 Mar; 19(3):457-63. PubMed ID: 6539131
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.